Minerva Surgical

Minerva Surgical EBITDA per Employee

The EBITDA per Employee of Minerva Surgical (UTRS) as of Nov 2, 2026 is -186,343.95 USD. In the previous year, EBITDA per Employee was -196,808.92 USD — a change of -5.32% (higher).

EBITDA per Employee

-186,343.95USD

YoY

-5.32%

Last updated:

EBITDA per Employee of Minerva Surgical is 2023 -186,343.95 USD. EBITDA per Employee of Minerva Surgical was 2022 -196,808.92 USD. It decreases by -5.32% higher compared to the previous year.

The Minerva Surgical EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-125,076.43 USD
Jan 1, 2020
-98,025.48 USD
Jan 1, 2021
-185,636.94 USD
Jan 1, 2022
-196,808.92 USD
Jan 1, 2023
-186,343.95 USD
The Minerva Surgical EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-186,343.95USD-5.32%
-196,808.92USD+6.02%
-185,636.94USD+89.38%
-98,025.48USD-21.63%
-125,076.43USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Minerva Surgical Stock analysis

What does Minerva Surgical do? Minerva Surgical, Inc. generates revenue through the commercialization of minimally invasive uterine healthcare solutions designed to treat abnormal uterine bleeding without necessitating hysterectomies. The company offers a suite of products targeting structural and non-structural causes of AUB, which are utilized by OB/GYNs in hospitals, ambulatory surgical centers, and physician offices. These devices address drawbacks of alternative treatments while preserving the uterus, appealing to healthcare providers seeking effective, non-invasive options for women's health. The firm's product line includes commercially available devices for minimally invasive alternatives to hysterectomy, specifically targeting the most common causes of AUB across various uterine anatomies. OB/GYNs across multiple medical settings purchase these solutions, leveraging their ability to address treatment limitations while avoiding unnecessary surgical interventions. The company's focus on preserving the uterus through non-hysterectomy methods differentiates its offerings in the women's health technology market. Minerva Surgical's revenue model relies on sales of its medical devices to healthcare providers, particularly OB/GYNs, who integrate the products into their treatment protocols for patients with abnormal uterine bleeding. The company's solutions are positioned as alternatives to traditional hysterectomy procedures, targeting a significant unmet need in women's healthcare. This approach allows the firm to capture market share by addressing both clinical and patient preference demands for less invasive care options. Minerva Surgical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Minerva Surgical stock

EBITDA per Employee of Minerva Surgical is -186,343.95 USD in 2023.

EBITDA per Employee of Minerva Surgical changed from -196,808.92 USD to -186,343.95 USD, representing a -5.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Minerva Surgical since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Minerva Surgical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Minerva Surgical

All Key Metrics — Minerva Surgical